The diagnostic landscape for thyroid nodules and thyroid cancer continues to change as new evidence, molecular diagnostic tools, and computational approaches become available. Clinicians must determine how these emerging technologies complement rather than replace clinical judgment, ultrasound findings, cytology, and established diagnostic pathways. A focused Grand Rounds presentation by an expert in thyroid nodule and thyroid cancer diagnosis will provide learners with an evidence-based framework for evaluating these evolving approaches and their appropriate incorporation into patient care. The educational need is particularly timely because the American Thyroid Association (ATA) recently published updated 2025 differentiated thyroid cancer management guidelines.

The evaluation and diagnosis of thyroid nodules and thyroid cancer have evolved substantially with advances in ultrasound risk stratification, cytologic assessment, molecular testing, and increasingly sophisticated diagnostic technologies. Clinicians may have variable familiarity with how newer diagnostic approaches should be integrated with established clinical and imaging assessment to accurately estimate malignancy risk and guide individualized management. It is imperative to translate emerging evidence and evolving diagnostic technologies, including artificial intelligence, into evidence-based clinical decision-making while avoiding unnecessary testing and procedures.